VP, Clinical Development, Amyloidosis and Rare Cardiology
AstraZeneca
About this role
The Vice President of Clinical Development for Amyloidosis & Rare Cardiology is a senior leadership role responsible for guiding the strategic direction and execution of clinical development programs from early phase to regulatory submission within Alexion. The position involves overseeing trial execution, fostering industry relationships, and ensuring regulatory compliance to support the company's growth in rare disease therapies.
Skills
About AstraZeneca
astrazeneca.comDigital Biology is part of AstraZeneca, a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines. The Digital Biology organization applies data science, computational biology, AI, and software engineering to accelerate drug discovery and translational research across therapeutic areas.
About AstraZeneca
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for AstraZeneca.